Skip to content

TriSalus Life Sciences, Inc. TLSI Finance Lease Liabilities

Finance Lease Liabilities at other companies

AngioDynamics logo
AngioDynamicsANGO
$2.41M-13.2%
Novanta logo
NovantaNOVT
$2.13M-28.5%
Plexus logo
PlexusPLXS
$40.67M+7.0%

Other financials

Income statement

See full
Revenue$8.9M-2.9%
Gross profit$7.7M0.0%
Operating income-$8.4M-14.8%
Net income$1.5M+115%
EPS (diluted)$0.03+108%

Balance sheet

See full
Cash & equivalents$56.6M+324%
Total debt$33.1M+4.4%
Total equity$12.8M+137%
Total assets$71.0M+148%

Cash flow

See full
Operating cash flow-$6.5M-44.0%
CapEx$141.0K-81.3%
Free cash flow-$6.6M-26.0%

Valuation

See full
Market cap$279.45M+49.6%
Enterprise value$255.97M+33.6%
P/S6.2×+1.0×

Profitability

See full
Gross margin85.1%-0.5pp
Operating margin-62.4%-16.8pp
Net margin-60.9%-13.4pp
FCF margin-45.2%-16.8pp

Returns & leverage

See full
Return on equity253.3%
Debt / equity2.6×
Current ratio5.8×+3.6×

Where this comes from

Reported directly by TriSalus Life Sciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityNoncurrent.

The official record: TriSalus Life Sciences, Inc.’s 10-K, filed March 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about TriSalus Life Sciences, Inc.'s finance lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TriSalus Life Sciences, Inc.'s finance lease liabilities?
TriSalus Life Sciences, Inc. (TLSI) reported finance lease liabilities of $42K in Q4 2025.
What is the long-term trend for TriSalus Life Sciences, Inc.'s finance lease liabilities?
Over 2 years (2023 to 2025), TriSalus Life Sciences, Inc.'s finance lease liabilities has grown at a -30.9% compound annual growth rate (CAGR), from $88K to $42K.
What does finance lease liabilities mean?
Present value of future payments on leases classified as finance leases under ASC 842 — treated similarly to debt on the balance sheet.